anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
== Comparisons with other drugs for type 2 diabetes == A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."
Senator Andy Kim of New Jersey described it as "unhinged and embarrassing", and Chris Murphy, a member of the Senate Foreign Affairs Committee, as "the ramblings of a man who has lost touch with reality". Vin Gupta, the medical analyst for NBC News, said the letter "crossed a line of proper adult behavior" and should have had a "more thorough public assessment of his neurological fitness," stating that Trump's behavior including his letter to Støre could be signs of early Alzheimer's or frontotemporal dementia. On January 21, 2026, while speaking in Davos, Trump would at least four times refer to Greenland as "Iceland." On January 22, 2026, Trump spoke before world leaders at a summit in Davos, and photographers captured photos of him with a large bruise on his left hand, unlike the bruise on his other hand, which the administration had to address publicly. Trump has publicly attributed the bruising to shaking hands, but he is accustomed to using his right hand, not his left. On January 29, 2026, shortly after the signing of Executive Order 14379[ws] "Addressing Addiction through the Great American Recovery Initiative", Trump and his cabinet dismissed news reporters from the Oval Office without an interview. Some social media users, including Rebekah Jones, speculated that the press conference ended abruptly due to Trump defecating himself. These accusations cited an unidentified sound and apparent reactions from Pam Bondi and Doug Burgum's wife Kathryn heard and seen in Forbes's live coverage.
== See also == Bruise, which is a hematoma caused by trauma Purpura secondary to clotting disorders Purpura hemorrhagica in horses Pigmented purpuric dermatosis Schamberg disease (progressive pigmentary purpura)
== See also == List of antidepressants Serotonin modulator and stimulator (SMS) Noradrenergic and specific serotonergic antidepressant (NaSSA) Norepinephrine-dopamine disinhibitor (NDDI) Selective serotonin reuptake inhibitor (SSRI) DSP-6745
=== Breast cancer === In studies of breast cancer prevention, lasofoxifene showed a 79% reduction in breast cancer incidence and an 83% reduction specific incidence of estrogen receptor-positive breast cancers, which is significantly higher than reductions found with the related SERMs tamoxifen and raloxifene. In accordance, a network meta-analysis of SERMs for breast cancer prevention found the highest reduction in risk with lasofoxifene of all the drugs. The reduction was even greater than that observed with aromatase inhibitors, which have generally been found to confer a greater risk reduction than SERMs. It also has shown promise in ESR1 mutant patients with 'approximately 40% of patients harboring this mutation'.
Sources: en.wikipedia.org
==== Reserve group antibiotics ==== This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Complementary:
=== Research === Similar assays can be performed for research purposes, detecting concentrations of potential clinical candidates like anti-fungal and asthma drugs. This technique is obviously useful in observing multiple species in collected samples, as well, but requires the use of standard solutions when information about species identity is sought out. It is used as a method to confirm results of synthesis reactions, as purity is essential in this type of research. However, mass spectrometry is still the more reliable way to identify species.
==== Criticism ==== David Handelsman has criticized terminology and understanding surrounding AAS in many publications. According to Handelsman, the pharmaceutical industry attempted to dissociate the so-called "androgenic" and "anabolic" effects of AAS in the mid-20th-century in order to create non-masculinizing anabolic agents that would be more suitable for use in women and children. However, this effort was unsuccessful and was abandoned by the 1970s. This was related to the subsequent discovery of a single androgen receptor (AR) mediating the effects of AAS in both muscle and reproductive tissue. In addition, it was related to misinterpretation of flawed animal androgen bioassays that had been employed to distinguish between androgenic or virilizing effects and anabolic or myotrophic effects (i.e., the Hershberger assay involving the unrepresentative levator ani muscle). In actuality, all AAS have essentially similar AR-mediated effects, even if some AAS may vary in potency in certain tissues like skin, hair follicles, and prostate gland based on their susceptibility to 5α-reduction (and associated metabolic amplification, inactivation, or lack thereof). Per Handelsman, the terms "anabolic steroid" and "anabolic–androgenic steroid" are obsolete, meaningless, and falsely distinguish these agents from androgens when there is no physiological basis for such distinction. It has also been noted that the use and distinction of the concepts "anabolic" and "androgenic", as well as the term "anabolic–androgenic steroid", are oxymoronic.
Louis, Missouri; Integrative Technologies for Advancing Scientific Cores ABRF 2014, 23–25 March, Albuquerque, New Mexico; Team Science and Big Data: Cores at the Frontier ABRF 2013, 2–5 March, Palm Springs, California; Tools for the Advancement of Convergence Science ABRF 2012, 17–20 March, Orlando, Florida; Learning From Biomolecules ABRF 2011, 19–22 February, San Antonio, Texas; Technologies to Enable Personalized Medicine ABRF 2010, 20–23 March, Sacramento, California; Translating Basic Research With Advances in Biomolecular Technology ABRF 2009, 7–10 February, Memphis, Tennessee; Application and Optimization of Existing and Emerging Biotechnologies ABRF 2008, 9–12 February, Salt Lake City, Utah; Enabling Technologies in the Life Sciences ABRF 2007, 31 March- 3 April, Tampa, Florida; Creating the Biological Roadmap ABRF 2006, 11–14 February, Long Beach, California; Integrating Science, Tools and Technologies with Systems Biology ABRF 2005, 5–8 February, Savannah, Georgia; BioMolecular Technologies: Discovery to Hypothesis ABRF 2004, 28 February – 2 March, Portland, Oregon; Integrating Technologies in Proteomics and Genomics ABRF 2003, 10–13 February, Denver, Colorado; Translating Biology Using Proteomics and Functional Genomics ABRF 2002, 9–12 March, Austin, Texas; Biomolecular Technologies: Tools for Discovery in Proteomics and Genomics ABRF 2001, 24–27 February, San Diego, CA; The New Biology: Technology for resolving Macromolecular Communications ABRF 2000, 19–22 February, Bellevue, Washington; From Singular to Global Analyses of Biological Systems ABRF 1999, 19–22 March, Durham, North Carolina; Bioinformatics and Biomolecular Technologies: Linking Genomes, Proteomes and Biochemistry ABRF 1998, 21–24 March, San Diego, California; From Genomes to Function – Technical Challenges of the Post-Genome Era ABRF 1997, 9–12 February, Baltimore, Maryland; Techniques at the Genome-Proteome Interface ABRF 1996, 30 March – 2 April, San Francisco, California; Biomolecular Techniques
Xaa-Pro dipeptidase, also known as prolidase, is an enzyme that in humans is encoded by the PEPD gene. Prolidase is an enzyme in humans that plays a crucial role in protein metabolism and collagen recycling through the catalysis of the rate-limiting step in these chemical reactions. This enzyme is coded by the gene PEPD (peptidase D), located on chromosome 19. Serum prolidase activity is also currently being explored as a biomarker for diseases.
Sources: en.wikipedia.org
=== Effects on the liver === Long-term use of kava has been associated with potential hepatotoxicity; however, the evidence remains inconclusive. Some kava extracts have demonstrated to be hepatotoxic. Concerns about this prompted warnings from health authorities in the United States, Australia, and Canada and led to kava being omitted from the US Pharmacopeia. The potential causes include contamination with toxic alkaloids from kava leaves and stems, differences in traditional versus commercial preparations, drug interactions affecting liver enzymes, and genetic variations in metabolism among populations. While kava appears safe in traditional South Pacific use, caution is advised, especially during pregnancy, for people with preexisting liver conditions, or when combined with alcohol consumption, prescription drugs or dietary supplements. The risk is higher with alcoholic or acetonic extracts, or concentrated forms like pills. Water-based kava extracts in moderate doses are considered safer, but should not be consumed with alcohol, particularly by those with a history of liver issues.
== Mechanism of action == Apixaban is a highly selective, orally bioavailable, and reversible direct inhibitor of free and clot-bound factor Xa. Factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade that is responsible for fibrin clot formation. Apixaban has no direct effect on platelet aggregation, but by inhibiting factor Xa, it indirectly decreases clot formation induced by thrombin.
=== Regulation by insulin in animals === In animals, regulation of blood glucose levels by the pancreas in conjunction with the liver is a vital part of homeostasis. The beta cells in the pancreatic islets are sensitive to the blood glucose concentration. A rise in the blood glucose concentration causes them to release insulin into the blood, which has an effect particularly on the liver, but also on fat and muscle cells, causing these tissues to remove glucose from the blood. When the blood sugar falls the pancreatic beta cells cease insulin production, but, instead, stimulate the neighboring pancreatic alpha cells to release glucagon into the blood. This, in turn, causes the liver to release glucose into the blood by breaking down stored glycogen, and by means of gluconeogenesis. If the fall in the blood glucose level is particularly rapid or severe, other glucose sensors cause the release of epinephrine from the adrenal glands into the blood. This has the same action as glucagon on glucose metabolism, but its effect is more pronounced. In the liver glucagon and epinephrine cause the phosphorylation of the key, regulated enzymes of glycolysis, fatty acid synthesis, cholesterol synthesis, gluconeogenesis, and glycogenolysis. Insulin has the opposite effect on these enzymes. The phosphorylation and dephosphorylation of these enzymes (ultimately in response to the glucose level in the blood) is the dominant manner by which these pathways are controlled in the liver, fat, and muscle cells.
In early 1984, just after South Africa and Angola had agreed to the principles of a peace settlement, UNITA had seized the opportunity to issue its own demanding conditions under which it would also accept the terms of a ceasefire. Savimbi requested a government of national unity with the MPLA in which he was granted a part, and threatened to begin attacking major cities if he was ignored. In this manner Savimbi sought to interlace conditionality over an SADF and FAPLA disengagement with his own conflict of interests with the Angolan regime. Although Botha approved of UNITA as an ostensibly anti-communist movement, he did nothing to impress Savimbi's demands on dos Santos. UNITA responded by raiding Sumbe, a settlement two hundred and sixty kilometres to the south of Luanda. That June, UNITA sabotaged the oil pipeline in Cabinda, kidnapping 16 British expatriate workers and a Portuguese technician. Six months later the insurgents raided Cafunfo, killing 100 FAPLA personnel. Most of these attacks were planned and executed from Jamba, a town in Cuando Cubango Province, which Savimbi had proclaimed UNITA's new national headquarters. Jamba had no prior strategic significance, possessed no agricultural base, and had limited access to fresh water, but it was located as far away from FAPLA bases as possible and within easy reach of SADF bases in Ovamboland and the Caprivi Strip. FAPLA had deserted the region for precisely this reason, withdrawing north after Operation Protea, but in the process left behind a power vacuum which Savimbi was quick to exploit.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.